Authors

Latest:

Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

Samuel Ahuno

Latest:

Ahuno on Bringing Precision Medicine in Cancer Care to Ghana

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

Ashish Manne, MBBS

Latest:

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Raymond Mailhot Vega, MD, MPH

Latest:

Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo

Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.

Cynthia Lynch, MD

Latest:

Treating Brain Metastases and the future of HER2+ mBC

Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.

Dr Stephen “Fred” Divers, American Oncology Network*

Latest:

Innovation Alone Doesn’t Save Lives. Delivery Does.

Fredrik Schjesvold, MD, PhD

Latest:

Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory Myeloma

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

Timothy M. Pawlik, MD, PhD, MPH

Latest:

Dr. Pawlik on Advances in Management of mCRC With Liver Metastases

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Zhubin Gahvari, MD, MS

Zhubin Gahvari, MD, MS, is an Assistant Professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, the University of Wisconsin Carbone Cancer Center

Latest:

CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies

As we plan for a future with solid tumor CAR T-cell therapy, we should be mindful of lessons learned from CAR T-cell agents for hematologic malignancies.

Julia Fadul, PharmD

Latest:

Clinical Perspectives: A 45-Year-Old Man With R/R CML

Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.

Marc S. Hoffmann, MD

Latest:

Translating BTK Inhibitor Data into Clinical Decision-Making

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Gloria Marquina, MD, PhD

Latest:

Dr Marquina on the Importance of Referring Patients With GIST to Specialized Sarcoma Centers

Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.

John K. Lee, MD, PhD

Latest:

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Pere Barba, MD, PhD

Latest:

Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALL

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Bradley Monk, MD, FACOG, FACS

Bradley Monk, MD, FACOG, FACS is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute and medical director of the Late-Stage Clinical Research Program.

Latest:

Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Diana Sutherland, NP

Latest:

Sutherland on the Promise of CDK4 Inhibitors in Metastatic Breast Cancer

Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.

Zhi Peng, MD

Latest:

Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ Cancer

Zhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.

Sima Rozati, MD, PhD

Latest:

CTCL Today: Remaining Unmet Needs in CTCL

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

Akriti G. Jain, MD

Akriti G. Jain, MD, is a hematologist and medical oncologist at the Cleveland Clinic in Ohio.

Latest:

Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

Kandra Horne, DNP, MSN, WHNP-BC

Latest:

Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.